FOLH1 and prostate carcinoma: Compared to PSMA-I&T, which is in clinical trials, and the FDA approved PSMA-11, in vitro the affinity of PSMA-1-DOTA was determined to be approximately fourfold greater using prostate cancer cells overexpressing the PSMA receptor (PC3pip cells) (p < 0.001).